Abstracts tagged "T Cell"

Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 0521 • ACR Convergence 2025
Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga³, Yujin Nishioka⁴, Masaki Nojima¹, Takumi Saito⁵, Yu Yamaji⁶, Tomoko Miyashita⁶, Makio Kusaoi⁷, Ken Yamaji⁵ and Naoto Tamura⁸, ¹Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ³Juntendo University, Tokyo, Japan, ⁴Juntendo University, Department of Internal Medicine and Rheumatology, Shizuoka, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, ⁷Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo, Tokyo, Japan, ⁸Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren's disease (pSD) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 0980 • ACR Convergence 2025
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
Carl Coyle¹, Wittaya Suwakulsiri², Lukas Andriessen³, Megan Soon⁴, Pascale Wehr⁵, Sumera Qureshi⁶, Christopher Altmann⁷, Annabelle Small⁸, Vincent Wong⁹, Andrew Cope⁶, Kevin Wei¹⁰, Hendrik Nel⁵, Mihir Wechalekar¹¹ and Ranjeny Thomas², ¹Kings College London, London, United Kingdom, ²Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ³Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia, ⁵University of Queensland, Woolloongabba, Queensland, Australia, ⁶King's College London, London, United Kingdom, ⁷Flinders University, Adelaide, Australia, ⁸Flinders University, Bedford Park, South Australia, Australia, ⁹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Flinders Medical Centre, Adelaide, Australia
Background/Purpose: Development of Rheumatoid Arthritis (RA) is strongly associated with specific HLA-DRB1 genotypes and the HLA-DR antigen binding groove, the shared epitope. HLA-B*08 also increases…
Abstract Number: 1005 • ACR Convergence 2025
CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
Yusuke Miyashita¹, Yang Yang², Madison Mangin³, Maryrose Hahn² and Margaret Chang², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease featured with recurrent inflammation in the same joints, a characteristic termed joint-specific memory. We previously demonstrated…
Abstract Number: 2303 • ACR Convergence 2025
Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Ruiling Feng, Bo Huang and Yuebo Jin, Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose interleukin 2 (Ld-IL2) is increasingly being explored as an immune-modulating treatment for autoimmune diseases which mainly affect T cell subsets. This study investigates…
Abstract Number: 0812 • ACR Convergence 2025
Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis
Chanhyuk Park¹, Helen Jarnagin², Asmaa Mohamed³, Noelle Kosarek⁴, Owen Wilkins¹, Fred Kolling¹, Yina Huang¹, Michael Whitfield⁵ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Charlottesville, VA, ⁴Dartmouth Geisel School of Medicine, Lebanon, NH, ⁵Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a progressive, chronic multi-system disorder of unknown etiology that is characterized by immune dysfunction, fibrosis, and loss of dermal white…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Dinesh Khanna¹, David Korman², Elana Bernstein³, Neil Kramer⁴, Vikas Majithia⁵, Philip J. Mease⁶, Georg Schett⁷, Jacques Azzi⁸, Richard Nash⁹, Ran Reshef³, Mohammad Cherry¹⁰, Ernesto Ayala⁵, Matthew Schwede¹¹, Monalisa Ghosh¹², Fabian Müller¹³, Alisha Desai¹⁴, San-San Ou¹⁵, Sharmila Das¹⁴, Jerill Thorpe¹⁶, Melissa Harnois¹⁴, Alexis Melton¹⁶, Ashley Koegel¹⁶ and Margrit Wiesendanger⁸, ¹University of Michigan, Ann Arbor, MI, ²Mountain Rheumatology, Denver, CO, ³Columbia University Irving Medical Center, New York, NY, ⁴Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Health One Cares, Denver, CO, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Swedish Cancer Institute, Seattle, WA, ¹²C. S. Mott Children's Hospital University of Michigan Health, Ann Arbor, MI, ¹³University Hospital of Erlangen, Erlangen, Germany, ¹⁴Bristol Myers Squibb, Princeton, NJ, ¹⁵Bristol Myers Squibb, Seattle, WA, ¹⁶Bristol Myers Squibb, Princeton
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…
Abstract Number: 0984 • ACR Convergence 2025
Interleukin-21 as a driver of CD8 T cell tissue resident memory and pathogenesis in dermatomyositis
Heather Ren¹, havell Markus², Mackenzie Sennett², Acela Cristina Rosado¹, Matthew Helm¹, Aron Lukacher², Amanda Nelson² and Galen Foulke¹, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine, Hershey, PA
Background/Purpose: Dermatomyositis is an autoimmune disease characterized by skin and muscle pathology and can feature significant morbidity and mortality from interstitial lung disease (ILD). Dermatomyositis…
Abstract Number: 1185 • ACR Convergence 2025
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Stéphane Mitrovic¹, Athénaïs Boucly², Maryvonnick Carmagnat³, Laurent Savale², Xavier Jaïs², Jean-luc Taupin³, Estibaliz Lazaro⁴, Emilie Berthoux⁵, nicolas schleinitz⁶, Maria-Rosa Ghigna⁷, kedra joanna¹, Xavier Mariette⁸, Céline Roussin⁹, Pierre Antoine Juge¹⁰, Marc Humbert², Olivier Sitbon², David Montani² and Bruno Fautrel¹¹, ¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²Kremlin Bicêtre Hospital, Pulmonology Department, Paris Saclay University, APHP, Le Kremlin Bicêtre, France, ³Saint Louis Hospital, Immunology laboratory, APHP, Paris, France, ⁴Internal Medicine Department, CHU Bordeaux, Bordeaux, France, ⁵Saint Joseph Sain Luc Hospital, Internal Medicine Department, Lyon, Lyon, France, ⁶Aix Marseille university, AP-HM, Marseille, France, ⁷Marie Lannelongue Hospital, Anatomopathology department, Le Plessis-Robinson, France, ⁸Université Paris-Saclay, Le Kremlin Bicetre, France, ⁹Centre Hospitalier Ouest Réunion, Saint Paul, France, ¹⁰Hopital Bichat, APHP, Paris, France, ¹¹Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 0850 • ACR Convergence 2025
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
Akinori Murakami¹, Rinko Akamine¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito², Ryu Watanabe³, Takayuki Fujii¹, Takeshi Iwasaki¹, Yuki Masuo⁴, Osamu Iri¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa⁵, Chikashi Terao⁶, Yukinori Okada⁷, Motomu Hashimoto³, Shuichi Matsuda¹, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Kyoto University / Kurashiki Central Hospital, Kyoto, Japan, ³Osaka Metropolitan University, Osaka, Japan, ⁴Graduate school of medicine, Kyoto University, Kyoto, Japan, ⁵Kyoto University / RIKEN, Kyoto, Japan, ⁶RIKEN, Tokyo, Japan, ⁷The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan
Background/Purpose: CD4+ T cells play a central role in the pathogenesis of human rheumatoid arthritis (RA). However, therapies targeting CD4+ T cell-derived humoral factors, including…
Abstract Number: 0985 • ACR Convergence 2025
Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
Hiroshi Kato¹, Lin Zhang¹, Mehrnaz Gharaee-Kermani², Amy Hurst¹, Rachael Bogle³, Alex Tsoi³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹Michigan Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a frequent manifestation of systemic lupus erythematosus (SLE) and remains an important contributor to morbidity in lupus patients. Despite…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].